Vaccine confusion as clots force jab switch for two million

17 June 2021 - Health authorities are scrambling to switch more than two million Australians aged under 60 to the ...

Read more →

Prescription drug price increases continue to outpace inflation

7 June 2021 - New AARP report shows even during pandemic consumers have had to pay more for medicines. ...

Read more →

Alzheimer’s drug is bonanza for Biogen, most likely at taxpayer expense

8 June 2021 - The FDA’s decision on Monday to approve a new Alzheimer’s medication over the fierce objections of ...

Read more →

Millions of J&J COVID-19 vaccines are at risk of expiring in June

8 June 2021 - States, hospitals try to reroute such vaccines, while efforts to export them face hurdles. ...

Read more →

AMA and Australian Government agree to strengthening the MBS review process and informed financial consent

8 June 2021 - The Australian Government and the Australian Medical Association have reached agreement to work together to co-design the ...

Read more →

Amicus Therapeutics announces United Kingdom’s MHRA grants early access to AT-GAA

8 June 2021 - Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the ...

Read more →

Glaukos Announces Australia’s TGA regulatory approval for Preserflo MicroShunt

8 June 2021 - Glaukos Corporation today announced that the TGA has granted regulatory approval for the Preserflo MicroShunt intended for ...

Read more →

U.S. FDA approves Prevnar 20, Pfizer’s pneumococcal 20 valent conjugate vaccine for adults ages 18 years or older

8 June 2021 - First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of ...

Read more →

Biogen faces tough questions over $56,000 a year price of newly approved Alzheimer’s drug

8 June 2021 - The biotech company’s price for the drug is higher than the $10,000 to $25,000 some Wall Street ...

Read more →

Alpha Tau receives breakthrough device designation from the FDA for Alpha DaRT

8 June 2021 - Alpha Tau Medical is pleased to announce that it has received a breakthrough device designation for Alpha ...

Read more →

VBI Vaccines granted FDA fast track designation for VBI-1901 for the treatment of recurrent GBM

8 June 2021 - Designation granted based on data from the Phase 1/2a study of VBI-1901 in recurrent GBM patients. ...

Read more →

Incyte announces U.S. FDA has extended the sNDA review period for ruxolitinib (Jakafi) in chronic graft versus host disease

8 June 2021 - Incyte today announced that the U.S. FDA has extended the review period for the supplemental new drug ...

Read more →

Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years

7 June 2021 - Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year ...

Read more →

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access Aduhelm

7 June 2021 - Value based agreements in progress with Cigna and other payers. ...

Read more →

Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate

8 June 2021 - It has all the makings of a bombastic drug pricing debate: a highly anticipated drug, widespread ...

Read more →

BerGenBio receives FDA fast track designation for bemcentinib/anti-PD-(L)1 combination in NSCLC

8 June 2021 - First recognition by a regulator of AXL positive patients as a target population. ...

Read more →